Quantification of PD-L1 Expression with 18F-BMS-986192 PET/CT in Patients with Advanced-Stage Non–Small Cell Lung Cancer
The aim of this work was to quantify the uptake of 18F-BMS-986192, a programmed cell death ligand 1 (PD-L1) adnectin PET tracer, in patients with non–small cell lung cancer. To this end, plasma input kinetic modeling of dynamic tumor uptake data with online arterial blood sampling was performed. In...
Gespeichert in:
| Veröffentlicht in: | The Journal of nuclear medicine (1978) 2020-10, Vol.61 (10), p.1455 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 10 |
| container_start_page | 1455 |
| container_title | The Journal of nuclear medicine (1978) |
| container_volume | 61 |
| creator | Huisman, Marc C Niemeijer, Anna-Larissa N Windhorst, Albert D Schuit, Robert C Leung, David Hayes, Wendy Poot, Alex Bahce, Idris Radonic, Teodora Oprea-Lager, Daniela E Hoekstra, Otto S Thunnissen, Erik Hendrikse, N Harry Smit, Egbert F de Langen, Adrianus J Boellaard, Ronald |
| description | The aim of this work was to quantify the uptake of 18F-BMS-986192, a programmed cell death ligand 1 (PD-L1) adnectin PET tracer, in patients with non–small cell lung cancer. To this end, plasma input kinetic modeling of dynamic tumor uptake data with online arterial blood sampling was performed. In addition, the accuracy of simplified uptake metrics such as SUV was investigated. Methods: Data from a study with 18F-BMS-986192 in patients with advanced-stage non–small cell lung cancer eligible for nivolumab treatment were used if a dynamic scan was available and lesions were present in the field of view of the dynamic scan. After injection of 18F-BMS-986192, a 60-min dynamic PET/CT scan was started, followed by a 30-min whole-body PET/CT scan. Continuous arterial and discrete arterial and venous blood sampling were performed to determine a plasma input function. Tumor time–activity curves were fitted by several plasma input kinetic models. Simplified uptake parameters included tumor-to-blood ratio as well as several SUV measures. Results: Twenty-two tumors in 9 patients were analyzed. The arterial plasma input single-tissue reversible compartment model with fitted blood volume fraction seems to be the most preferred model as it best fitted 11 of 18 tumor time–activity curves. The distribution volume (VT) ranged from 0.4 to 4.8 mL⋅cm−3. Similar values were obtained with an image-derived input function. From the simplified measures, SUV normalized for body weight at 50 and 67 min after injection correlated best with VT, with an R2 of more than 0.9. Conclusion: A single-tissue reversible model can be used to quantify tumor uptake of the PD-L1 PET tracer 18F-BMS-986192. SUV at 60 min after injection, normalized for body weight, is an accurate simplified parameter for uptake assessment of baseline studies. To assess its predictive value for response evaluation during programmed cell death protein 1 or PD-L1 immune checkpoint inhibition, further validation of SUV against VT based on an image-derived input function is recommended. |
| doi_str_mv | 10.2967/jnumed.119.240895 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2453912853</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2453912853</sourcerecordid><originalsourceid>FETCH-LOGICAL-p1045-4086f94ac91d564cd808b991088d2ff821c4274b38fc4279f1e5820faf90e65e3</originalsourceid><addsrcrecordid>eNotT0tOwzAUtBBIlMIB2Fli7dbPsd3nZQktIAUoallXbmKXVK0T8gHEijtwQ05CqrKZeRrNzNMQcgl8IIweDTeh3blsAGAGQnI06oj0QEWKKa1Hx6THQQNTiqtTclbXG865RsQe-XpubWhyn6e2yYtAC09nNywBOvksK1fXe-0jb14p4JRdP8yZQQ1G0NlkMYwXNA901gVdaOqDbZy925C6jM0bu3b0sQi_3z_znd1uaew6SNqwpvHeUp2TE2-3tbv45z55mU4W8R1Lnm7v43HCSuBSsW6N9kba1ECmtEwz5LgyBjhiJrxHAakUI7mK0O8P48EpFNxbb7jTykV9cnXoLavirXV1s9wUbRW6l0shVWRAoIqiPyCMXgg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2453912853</pqid></control><display><type>article</type><title>Quantification of PD-L1 Expression with 18F-BMS-986192 PET/CT in Patients with Advanced-Stage Non–Small Cell Lung Cancer</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Huisman, Marc C ; Niemeijer, Anna-Larissa N ; Windhorst, Albert D ; Schuit, Robert C ; Leung, David ; Hayes, Wendy ; Poot, Alex ; Bahce, Idris ; Radonic, Teodora ; Oprea-Lager, Daniela E ; Hoekstra, Otto S ; Thunnissen, Erik ; Hendrikse, N Harry ; Smit, Egbert F ; de Langen, Adrianus J ; Boellaard, Ronald</creator><creatorcontrib>Huisman, Marc C ; Niemeijer, Anna-Larissa N ; Windhorst, Albert D ; Schuit, Robert C ; Leung, David ; Hayes, Wendy ; Poot, Alex ; Bahce, Idris ; Radonic, Teodora ; Oprea-Lager, Daniela E ; Hoekstra, Otto S ; Thunnissen, Erik ; Hendrikse, N Harry ; Smit, Egbert F ; de Langen, Adrianus J ; Boellaard, Ronald</creatorcontrib><description>The aim of this work was to quantify the uptake of 18F-BMS-986192, a programmed cell death ligand 1 (PD-L1) adnectin PET tracer, in patients with non–small cell lung cancer. To this end, plasma input kinetic modeling of dynamic tumor uptake data with online arterial blood sampling was performed. In addition, the accuracy of simplified uptake metrics such as SUV was investigated. Methods: Data from a study with 18F-BMS-986192 in patients with advanced-stage non–small cell lung cancer eligible for nivolumab treatment were used if a dynamic scan was available and lesions were present in the field of view of the dynamic scan. After injection of 18F-BMS-986192, a 60-min dynamic PET/CT scan was started, followed by a 30-min whole-body PET/CT scan. Continuous arterial and discrete arterial and venous blood sampling were performed to determine a plasma input function. Tumor time–activity curves were fitted by several plasma input kinetic models. Simplified uptake parameters included tumor-to-blood ratio as well as several SUV measures. Results: Twenty-two tumors in 9 patients were analyzed. The arterial plasma input single-tissue reversible compartment model with fitted blood volume fraction seems to be the most preferred model as it best fitted 11 of 18 tumor time–activity curves. The distribution volume (VT) ranged from 0.4 to 4.8 mL⋅cm−3. Similar values were obtained with an image-derived input function. From the simplified measures, SUV normalized for body weight at 50 and 67 min after injection correlated best with VT, with an R2 of more than 0.9. Conclusion: A single-tissue reversible model can be used to quantify tumor uptake of the PD-L1 PET tracer 18F-BMS-986192. SUV at 60 min after injection, normalized for body weight, is an accurate simplified parameter for uptake assessment of baseline studies. To assess its predictive value for response evaluation during programmed cell death protein 1 or PD-L1 immune checkpoint inhibition, further validation of SUV against VT based on an image-derived input function is recommended.</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>DOI: 10.2967/jnumed.119.240895</identifier><language>eng</language><publisher>New York: Society of Nuclear Medicine</publisher><subject>Apoptosis ; Baseline studies ; Blood ; Blood volume ; Body weight ; Cell death ; Computed tomography ; Field of view ; Fluorine isotopes ; Immune checkpoint inhibitors ; Injection ; Lung cancer ; Mathematical models ; Medical imaging ; Monoclonal antibodies ; Non-small cell lung carcinoma ; Parameters ; PD-L1 protein ; Plasma ; Positron emission ; Sampling ; Targeted cancer therapy ; Tomography ; Tumors</subject><ispartof>The Journal of nuclear medicine (1978), 2020-10, Vol.61 (10), p.1455</ispartof><rights>Copyright Society of Nuclear Medicine Oct 1, 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids></links><search><creatorcontrib>Huisman, Marc C</creatorcontrib><creatorcontrib>Niemeijer, Anna-Larissa N</creatorcontrib><creatorcontrib>Windhorst, Albert D</creatorcontrib><creatorcontrib>Schuit, Robert C</creatorcontrib><creatorcontrib>Leung, David</creatorcontrib><creatorcontrib>Hayes, Wendy</creatorcontrib><creatorcontrib>Poot, Alex</creatorcontrib><creatorcontrib>Bahce, Idris</creatorcontrib><creatorcontrib>Radonic, Teodora</creatorcontrib><creatorcontrib>Oprea-Lager, Daniela E</creatorcontrib><creatorcontrib>Hoekstra, Otto S</creatorcontrib><creatorcontrib>Thunnissen, Erik</creatorcontrib><creatorcontrib>Hendrikse, N Harry</creatorcontrib><creatorcontrib>Smit, Egbert F</creatorcontrib><creatorcontrib>de Langen, Adrianus J</creatorcontrib><creatorcontrib>Boellaard, Ronald</creatorcontrib><title>Quantification of PD-L1 Expression with 18F-BMS-986192 PET/CT in Patients with Advanced-Stage Non–Small Cell Lung Cancer</title><title>The Journal of nuclear medicine (1978)</title><description>The aim of this work was to quantify the uptake of 18F-BMS-986192, a programmed cell death ligand 1 (PD-L1) adnectin PET tracer, in patients with non–small cell lung cancer. To this end, plasma input kinetic modeling of dynamic tumor uptake data with online arterial blood sampling was performed. In addition, the accuracy of simplified uptake metrics such as SUV was investigated. Methods: Data from a study with 18F-BMS-986192 in patients with advanced-stage non–small cell lung cancer eligible for nivolumab treatment were used if a dynamic scan was available and lesions were present in the field of view of the dynamic scan. After injection of 18F-BMS-986192, a 60-min dynamic PET/CT scan was started, followed by a 30-min whole-body PET/CT scan. Continuous arterial and discrete arterial and venous blood sampling were performed to determine a plasma input function. Tumor time–activity curves were fitted by several plasma input kinetic models. Simplified uptake parameters included tumor-to-blood ratio as well as several SUV measures. Results: Twenty-two tumors in 9 patients were analyzed. The arterial plasma input single-tissue reversible compartment model with fitted blood volume fraction seems to be the most preferred model as it best fitted 11 of 18 tumor time–activity curves. The distribution volume (VT) ranged from 0.4 to 4.8 mL⋅cm−3. Similar values were obtained with an image-derived input function. From the simplified measures, SUV normalized for body weight at 50 and 67 min after injection correlated best with VT, with an R2 of more than 0.9. Conclusion: A single-tissue reversible model can be used to quantify tumor uptake of the PD-L1 PET tracer 18F-BMS-986192. SUV at 60 min after injection, normalized for body weight, is an accurate simplified parameter for uptake assessment of baseline studies. To assess its predictive value for response evaluation during programmed cell death protein 1 or PD-L1 immune checkpoint inhibition, further validation of SUV against VT based on an image-derived input function is recommended.</description><subject>Apoptosis</subject><subject>Baseline studies</subject><subject>Blood</subject><subject>Blood volume</subject><subject>Body weight</subject><subject>Cell death</subject><subject>Computed tomography</subject><subject>Field of view</subject><subject>Fluorine isotopes</subject><subject>Immune checkpoint inhibitors</subject><subject>Injection</subject><subject>Lung cancer</subject><subject>Mathematical models</subject><subject>Medical imaging</subject><subject>Monoclonal antibodies</subject><subject>Non-small cell lung carcinoma</subject><subject>Parameters</subject><subject>PD-L1 protein</subject><subject>Plasma</subject><subject>Positron emission</subject><subject>Sampling</subject><subject>Targeted cancer therapy</subject><subject>Tomography</subject><subject>Tumors</subject><issn>0161-5505</issn><issn>1535-5667</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNotT0tOwzAUtBBIlMIB2Fli7dbPsd3nZQktIAUoallXbmKXVK0T8gHEijtwQ05CqrKZeRrNzNMQcgl8IIweDTeh3blsAGAGQnI06oj0QEWKKa1Hx6THQQNTiqtTclbXG865RsQe-XpubWhyn6e2yYtAC09nNywBOvksK1fXe-0jb14p4JRdP8yZQQ1G0NlkMYwXNA901gVdaOqDbZy925C6jM0bu3b0sQi_3z_znd1uaew6SNqwpvHeUp2TE2-3tbv45z55mU4W8R1Lnm7v43HCSuBSsW6N9kba1ECmtEwz5LgyBjhiJrxHAakUI7mK0O8P48EpFNxbb7jTykV9cnXoLavirXV1s9wUbRW6l0shVWRAoIqiPyCMXgg</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Huisman, Marc C</creator><creator>Niemeijer, Anna-Larissa N</creator><creator>Windhorst, Albert D</creator><creator>Schuit, Robert C</creator><creator>Leung, David</creator><creator>Hayes, Wendy</creator><creator>Poot, Alex</creator><creator>Bahce, Idris</creator><creator>Radonic, Teodora</creator><creator>Oprea-Lager, Daniela E</creator><creator>Hoekstra, Otto S</creator><creator>Thunnissen, Erik</creator><creator>Hendrikse, N Harry</creator><creator>Smit, Egbert F</creator><creator>de Langen, Adrianus J</creator><creator>Boellaard, Ronald</creator><general>Society of Nuclear Medicine</general><scope>4T-</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope></search><sort><creationdate>20201001</creationdate><title>Quantification of PD-L1 Expression with 18F-BMS-986192 PET/CT in Patients with Advanced-Stage Non–Small Cell Lung Cancer</title><author>Huisman, Marc C ; Niemeijer, Anna-Larissa N ; Windhorst, Albert D ; Schuit, Robert C ; Leung, David ; Hayes, Wendy ; Poot, Alex ; Bahce, Idris ; Radonic, Teodora ; Oprea-Lager, Daniela E ; Hoekstra, Otto S ; Thunnissen, Erik ; Hendrikse, N Harry ; Smit, Egbert F ; de Langen, Adrianus J ; Boellaard, Ronald</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p1045-4086f94ac91d564cd808b991088d2ff821c4274b38fc4279f1e5820faf90e65e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Apoptosis</topic><topic>Baseline studies</topic><topic>Blood</topic><topic>Blood volume</topic><topic>Body weight</topic><topic>Cell death</topic><topic>Computed tomography</topic><topic>Field of view</topic><topic>Fluorine isotopes</topic><topic>Immune checkpoint inhibitors</topic><topic>Injection</topic><topic>Lung cancer</topic><topic>Mathematical models</topic><topic>Medical imaging</topic><topic>Monoclonal antibodies</topic><topic>Non-small cell lung carcinoma</topic><topic>Parameters</topic><topic>PD-L1 protein</topic><topic>Plasma</topic><topic>Positron emission</topic><topic>Sampling</topic><topic>Targeted cancer therapy</topic><topic>Tomography</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huisman, Marc C</creatorcontrib><creatorcontrib>Niemeijer, Anna-Larissa N</creatorcontrib><creatorcontrib>Windhorst, Albert D</creatorcontrib><creatorcontrib>Schuit, Robert C</creatorcontrib><creatorcontrib>Leung, David</creatorcontrib><creatorcontrib>Hayes, Wendy</creatorcontrib><creatorcontrib>Poot, Alex</creatorcontrib><creatorcontrib>Bahce, Idris</creatorcontrib><creatorcontrib>Radonic, Teodora</creatorcontrib><creatorcontrib>Oprea-Lager, Daniela E</creatorcontrib><creatorcontrib>Hoekstra, Otto S</creatorcontrib><creatorcontrib>Thunnissen, Erik</creatorcontrib><creatorcontrib>Hendrikse, N Harry</creatorcontrib><creatorcontrib>Smit, Egbert F</creatorcontrib><creatorcontrib>de Langen, Adrianus J</creatorcontrib><creatorcontrib>Boellaard, Ronald</creatorcontrib><collection>Docstoc</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>The Journal of nuclear medicine (1978)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huisman, Marc C</au><au>Niemeijer, Anna-Larissa N</au><au>Windhorst, Albert D</au><au>Schuit, Robert C</au><au>Leung, David</au><au>Hayes, Wendy</au><au>Poot, Alex</au><au>Bahce, Idris</au><au>Radonic, Teodora</au><au>Oprea-Lager, Daniela E</au><au>Hoekstra, Otto S</au><au>Thunnissen, Erik</au><au>Hendrikse, N Harry</au><au>Smit, Egbert F</au><au>de Langen, Adrianus J</au><au>Boellaard, Ronald</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quantification of PD-L1 Expression with 18F-BMS-986192 PET/CT in Patients with Advanced-Stage Non–Small Cell Lung Cancer</atitle><jtitle>The Journal of nuclear medicine (1978)</jtitle><date>2020-10-01</date><risdate>2020</risdate><volume>61</volume><issue>10</issue><spage>1455</spage><pages>1455-</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><abstract>The aim of this work was to quantify the uptake of 18F-BMS-986192, a programmed cell death ligand 1 (PD-L1) adnectin PET tracer, in patients with non–small cell lung cancer. To this end, plasma input kinetic modeling of dynamic tumor uptake data with online arterial blood sampling was performed. In addition, the accuracy of simplified uptake metrics such as SUV was investigated. Methods: Data from a study with 18F-BMS-986192 in patients with advanced-stage non–small cell lung cancer eligible for nivolumab treatment were used if a dynamic scan was available and lesions were present in the field of view of the dynamic scan. After injection of 18F-BMS-986192, a 60-min dynamic PET/CT scan was started, followed by a 30-min whole-body PET/CT scan. Continuous arterial and discrete arterial and venous blood sampling were performed to determine a plasma input function. Tumor time–activity curves were fitted by several plasma input kinetic models. Simplified uptake parameters included tumor-to-blood ratio as well as several SUV measures. Results: Twenty-two tumors in 9 patients were analyzed. The arterial plasma input single-tissue reversible compartment model with fitted blood volume fraction seems to be the most preferred model as it best fitted 11 of 18 tumor time–activity curves. The distribution volume (VT) ranged from 0.4 to 4.8 mL⋅cm−3. Similar values were obtained with an image-derived input function. From the simplified measures, SUV normalized for body weight at 50 and 67 min after injection correlated best with VT, with an R2 of more than 0.9. Conclusion: A single-tissue reversible model can be used to quantify tumor uptake of the PD-L1 PET tracer 18F-BMS-986192. SUV at 60 min after injection, normalized for body weight, is an accurate simplified parameter for uptake assessment of baseline studies. To assess its predictive value for response evaluation during programmed cell death protein 1 or PD-L1 immune checkpoint inhibition, further validation of SUV against VT based on an image-derived input function is recommended.</abstract><cop>New York</cop><pub>Society of Nuclear Medicine</pub><doi>10.2967/jnumed.119.240895</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0161-5505 |
| ispartof | The Journal of nuclear medicine (1978), 2020-10, Vol.61 (10), p.1455 |
| issn | 0161-5505 1535-5667 |
| language | eng |
| recordid | cdi_proquest_journals_2453912853 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Apoptosis Baseline studies Blood Blood volume Body weight Cell death Computed tomography Field of view Fluorine isotopes Immune checkpoint inhibitors Injection Lung cancer Mathematical models Medical imaging Monoclonal antibodies Non-small cell lung carcinoma Parameters PD-L1 protein Plasma Positron emission Sampling Targeted cancer therapy Tomography Tumors |
| title | Quantification of PD-L1 Expression with 18F-BMS-986192 PET/CT in Patients with Advanced-Stage Non–Small Cell Lung Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T20%3A45%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quantification%20of%20PD-L1%20Expression%20with%2018F-BMS-986192%20PET/CT%20in%20Patients%20with%20Advanced-Stage%20Non%E2%80%93Small%20Cell%20Lung%20Cancer&rft.jtitle=The%20Journal%20of%20nuclear%20medicine%20(1978)&rft.au=Huisman,%20Marc%20C&rft.date=2020-10-01&rft.volume=61&rft.issue=10&rft.spage=1455&rft.pages=1455-&rft.issn=0161-5505&rft.eissn=1535-5667&rft_id=info:doi/10.2967/jnumed.119.240895&rft_dat=%3Cproquest%3E2453912853%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2453912853&rft_id=info:pmid/&rfr_iscdi=true |